Thrombotic Microangiopathies: all 52 studies

Page 1 of 1. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of Eculizumab in High-risk TA-TMARecruitingNCT07707687Phase 2
• The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathyRecruitingNCT07705789Not applicable
• TGD001 Treatment in Thrombotic MicroangiopathiesRecruitingNCT07459114Phase 1/2
• Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic MicroangiopathyRecruitingNCT07347990Not applicable
• Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA CenterRecruitingNCT07205861
• Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult PatientsRecruitingNCT07059026
• Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669
• Italian iTTP RegistryRecruitingNCT06376786
• Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic PurpuraRecruitingNCT06291025Not applicable
• Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic MicroangiopathyRecruitingNCT06102694
• Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With EculizumabRecruitingNCT06098378
• Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA StudyNot yet recruitingNCT05996679
• French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"RecruitingNCT05991245
• Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)RecruitingNCT05935215Phase 3
• Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMARecruitingNCT05855083Phase 2
• Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSRecruitingNCT05795140Phase 3
• Construction of a Database for TMARecruitingNCT05634928
• Complement Prospective Evaluation of Thrombotic Microangiopathy on EndotheliumRecruitingNCT04745195
• TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT PatientsRecruitingNCT04098445
• OMS721 Compassionate Use in Patients With Thrombotic MicroangiopathyAvailableNCT02355782
• Atypical Hemolytic-Uremic Syndrome (aHUS) RegistryRecruitingNCT01522183
• A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantationCompletedNCT05148299Phase 2Results posted
• Nomacopan (rVA576) in Transplant Associated Thrombotic MicroangiopathyTerminatedNCT04784455Phase 3Results posted
• Ravulizumab in Thrombotic Microangiopathy Associated With a TriggerTerminatedNCT04743804Phase 3Results posted
• Study of Ravulizumab in Pediatric Participants With HSCT-TMACompletedNCT04557735Phase 3Results posted
• Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantCompletedNCT04543591Phase 3Results posted
• Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant RecipientsCompletedNCT03518203Phase 2Results posted
• Defibrotide TMA Prophylaxis Pilot TrialCompletedNCT03384693Phase 2Results posted
• A Safety and Efficacy Study of NAC in Patients With TA-TMACompletedNCT03252925Phase 3Results posted
• Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeTerminatedNCT03205995Phase 3Results posted
• Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesCompletedNCT02222545Phase 2Results posted
• A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).CompletedNCT07732361
• N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic MicroangiopathyActive, not recruitingNCT07279610Phase 2/3
• The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnNCT06291415Phase 1
• Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for NeuroblastomaWithdrawnNCT06182410Phase 2
• Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic MicroangiopathiesWithdrawnNCT05702996Phase 3
• Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus ErythematosusWithdrawnNCT05504187Phase 2
• Study in Adult and Pediatric Patients With HSCT-TMAWithdrawnNCT04970004
• Risk Factors and the Effect of Plasma Exchange on Prognosis of Pregnancy-related Thrombotic MicroangiopathiesStatus unknownNCT04949698
• Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyCompletedNCT04889430Phase 3
• Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)CompletedNCT04859608Phase 3
• Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical OutcomeStatus unknownNCT04845022
• Observational Study of Elizaria® in aHUS PatientsCompletedNCT04749810
• Ravulizumab and COVID-19Status unknownNCT04570397Phase 3
• Single Patient Expanded Access Treatment Plan For The Investigational Product NarsoplimabApproved for marketingNCT04247906
• TTP and aHUS in Complicated PregnanciesStatus unknownNCT03605511
• A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeWithdrawnNCT03303313Phase 2
• Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell TransplantsCompletedNCT02604420
• Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)Status unknownNCT02373267
• Early Predictive Factors of Cardiac and Cerebral Involvement in TMACompletedNCT02134171Not applicable
• Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic MicroangiopathyTerminatedNCT00726544Phase 2
• International Registry and Biorepository for TMA(Thrombotic Microangiopathy)TerminatedNCT00593229

← Thrombotic Microangiopathies overview